Psicofarma, S.A. De C.V.
6
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
2 terminated/withdrawn out of 6 trials
50.0%
-36.5% vs industry average
50%
3 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety Disorder
Role: lead
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
Role: collaborator
Hydralazine Valproate for Cervical Cancer
Role: collaborator
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
Role: collaborator
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer
Role: collaborator
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
Role: collaborator
All 6 trials loaded